Cerus Corporation

CERS ·Healthcare, Medical Devices, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-15.6M $-20.9M $-37.5M $-42.8M $-54.4M $-59.9M $-71.2M $-57.6M
Depreciation & Amortization $1.4M $1.9M $2.6M $3.0M $3.1M $3.1M $2.4M $1.4M
Depreciation — — — — — — — —
Amortization — — — — — — — —
Stock-Based Compensation $22.9M $22.9M $20.3M $24.5M $23.6M $18.0M $13.3M $10.4M
Net Cash from Operating Activities $4.8M $11.4M $-43.2M $-25.6M $-33.9M $-41.8M $-65.5M $-31.2M
Investing Activities
Capital Expenditures $3.7M $2.8M $4.6M $2.0M $910.0K $1.6M $8.9M $1.1M
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-6.2M $-8.1M $8.6M $8.5M $12.7M $-49.6M $28.2M $-43.8M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $231.0K $5.0M $10.7M $4.2M $34.3M $91.8M $43.5M $92.8M
Net Change in Cash $-761.0K $8.0M $-24.0M $-13.7M $12.1M $1.5M $5.8M $17.7M
Free Cash Flow $1.1M $8.5M $-47.8M $-27.6M $-34.8M $-43.4M $-74.4M $-32.4M
← Newer Page 1 of 3 Older →